TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU

Hepatology

Volumn 44, Issue 1, 2006, Pages 205-215

  Zhao, Jian ^a,b   Zhang, Xia ^a   Shi, Mei ^a   Xu, Hao ^a   Jin, Jun ^a   Ni, Haidong ^a   Yang, Silei ^a   Dai, Jianxin ^a,b   Wu, Mengchao ^a   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b E Institute of Immunology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOTOXIC AGENT; FLUOROURACIL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEIN TIP30; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ACETYLTRANSFERASES; ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENICITY TESTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, NEOPLASM; FLOW CYTOMETRY; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 33745922882     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21213     Document Type: Article

References (34)

1. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573-588.
2. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997;14:2167-2173.
3. NicAmhlaoibh R, Shtivelman E. Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene 2001;20:270-275.
4. Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 1999;274:13338-13344.
5. Hewitt RE, Brown KE, Corcoran M, Stetler-Stevenson WG. Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line. J Pathol 2000;192:455-459.
6. Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, et al. TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res 2003;63:8763-8767.
7. Whitman S, Wang X, Shalaby R, Shtivelman E. Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol 2000;20:583-593.
8. Xiao H, Palhan V, Yang Y, Roeder RG. TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. EMBO J 2000;19:956-963.
9. King FW, Shtivelman E. Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol 2004;24:7091-7101.
10. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H. TIP30 interacts with an estrogen receptor α-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 2004;279:27781-27789.
11. El Omari K, Bird LE, Nichols CE, Ren J, Stammers DK. Crystal structure of CC3 (TIP30): implications for its role as a tumor suppressor. J Biol Chem 2005;280:18229-18236.
12. Shi Y, Shi Y. Metabolic enzymes and coenzymes in transcription-a direct link between metabolism and transcription? Trends Genet 2004;20:445-452.
13. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-2514.
14. -ΔΔCT method. Methods 2005;25:402-408.
15. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. HEPATOLOGY 2001;34:55-61.
16. Watanabe J, Kushihata F, Honda K, Mominoki K, Matsuda S, Kobayashi N. Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 2002;21:515-519.
17. Takahashi M, Saito H, Okuyama T, Miyashita T, Kosuga M, Sumisa F, et al. Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody-mediated apoptosis. J Hepatol 1999;31:315-322.
18. Chun E, Lee KY. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2004;315:771-779.
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of P53. Nature 1997;387:296-299.
20. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
21. Kim Y, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells. HEPATOLOGY 2002;36:1498-1508.
22. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. HEPATOLOGY 2003;32:482-490.
23. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitization of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004;11:S86-S96.
24. Ponder BA. Cancer genetics. Nature 2001;411:336-341.
25. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
26. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
27. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature Rev Cancer 2002;2:594-604.
28. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G. Functional inactivation but not structural mutation of p53 cause liver cancer. Nat Genet 1995;9:41-47.
29. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997;94:14707-14712.
30. Qiu SJ, Ye SL, Wu ZQ, Tang ZY, Liu YK. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998;24:253-258.
31. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000;20:209-215.
32. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001;20:7104-7109.
33. Peng CY, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, et al. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res 2002;22:1265-1271.
34. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;52:459-462.